Journal Mobile Options
Table of Contents
Vol. 67, No. 1, 2013
Issue release date: December 2012
Neuropsychobiology 2013;67:14–24

Assessment of Cognitive Impairments and Seizure Characteristics in Electroconvulsive Therapy with and without Sodium Valproate in Manic Patients

Haghighi M. · Bajoghli H. · Bigdelou G. · Jahangard L. · Holsboer-Trachsler E. · Brand S.
aResearch Center for Behavioral Disorders and Substance Abuse, Hamadan University of Medical Sciences, Hamadan, and bPsychiatry and Psychology Research Center (PPRC), Roozbeh Hospital, Tehran University of Medical Sciences, Tehran, Iran; cCenter for Affective, Stress and Sleep Disorders, Psychiatric Hospital of the University of Basel, Basel, Switzerland

Individual Users: Register with Karger Login Information

Please create your User ID & Password

Contact Information

I have read the Karger Terms and Conditions and agree.

To view the fulltext, please log in

To view the pdf, please log in


Objectives: The aim of the present study was two-fold: (1) to compare, in a controlled double-blind quasi-randomized clinical trial, treatment improvements, treatment outcome, and cognitive impairments in patients suffering from current manic episodes, while treated with electroconvulsive therapy (ECT) with and without concurrent sodium valproate therapy, and (2) to compare ECT seizure characteristics in patients with and without concurrent sodium valproate therapy. Methods: A total of 40 inpatients (mean age = 31.80 years, SD = 8.06; 75% males) suffering from bipolar disorders and currently in a manic state took part in the study. They were quasi-randomly assigned either to the target (continuation of sodium valproate administration) or to the control group (discontinuation of sodium valproate administration). All patients underwent bifrontal ECT for at least 6 sessions. Improvements and cognitive impairments were assessed, and seizure characteristics (duration, threshold) were also recorded. Results: Manic episodes improved significantly over time, and irrespective of the group (target vs. control group). Cognitive impairments did not alter over time or between groups. Seizure duration did not change over time or between groups. Seizure threshold did not change over time, but was lower in the target than in the control group. Conclusions: Continuing the administration of sodium valproate neither adversely affects, nor enhances cognitive impairments or seizure duration, but reduces seizure threshold during ECT in patients suffering from manic episodes. Moreover, gender appeared to be more strongly associated with cognitive impairment and seizure activity than treatment approaches in these psychiatric conditions.

Copyright / Drug Dosage

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher or, in the case of photocopying, direct payment of a specified fee to the Copyright Clearance Center.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in goverment regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.


  1. Merikangas KR, Akiskal HS, Angst J, et al: Lifetime and 12-month prevalence of bipolar spectrum disorder in the National Comorbidity Survey replication. Arch Gen Psychiatry 2007;64:543–552.
  2. Holtmann M, Duketis E, Poustka L, et al: Bipolar disorder in children and adolescents in Germany: national trends in the rates of inpatients, 2000–2007. Bipolar Disord 2010;12:155–163.
  3. Duffy A: The early natural history of bipolar disorder: what we have learned from longitudinal high-risk research. Can J Psychiatry 2010;55:477–485.
  4. Sadock BJ, Sadock VA: Kaplan and Sadock’s Synapsis of Psychiatry: Behavioral Sciences/Clinical Psychiatry. Philadelphia, Lippincott Williams & Wilkins, 2007.
  5. American Psychiatric Association Committee on Electroconvulsive Therapy: The Practice of Electroconvulsive Therapy: Recommendations for Treatment, Training, and Privileging, ed 2. Washington, American Psychiatric Association, 2001.
  6. Versiani M, Cheniaux E, Landeira-Fernandez J: Efficacy and safety of electoconvulsive therapy in the treatment of bipolar disorder. J ECT 2011;27:153–164.
  7. Sienaert P: What we have learned about electroconvulsive therapy and its relevance for the practicing psychiatrist. Can J Psychiatry 2011;56:5–12.
  8. Abrams R: Electroconvulsive Therapy, ed 4. New York, Oxford University Press, 2002, pp 17–42.
  9. National Institutes of Health: Electroconvulsive Therapy. NIH Consensus Statement Online. Bethesda, National Institutes of Health, 1985. (accessed November 2, 2011).
  10. Reisner AD: The electroconvulsive therapy controversy: evidence and ethics. Neuropsychol Rev 2003;13:199–219.
  11. Practice guideline for the treatment of patients with bipolar disorder. American Psychiatric Association. Am J Psychiatry 1994;151(12 suppl):1–36.
  12. Payne NA, Prudic J: Electroconvulsive therapy. 1. A perspective on the evolution and current practice of ECT. J Psychiatr Pract 2009;15:346–368.
  13. De la Serna E, Flamarique I, Castro-Fornieles J, et al: Two-year follow-up of cognitive functions in schizophrenia spectrum disorders of adolescent patients treated with electroconvulsive therapy. J Child Adolesc Psychopharmacol 2011;21:611–619.
  14. Cohen D, Taleb O, Flament M, et al: Absence of cognitive impairment at long-term follow-up in adolescents treated with ECT for severe mood disorder. Am J Psychiatry 2010;157:460–462.
  15. Ghaziuddin N, Laughrin D, Giordani B: Cognitive side effects of electroconvulsive therapy in adolescents. J Child Adolesc Psychopharmacol 2000;10:269–276.
  16. Rami L, Goti X, Ferrer J, et al: Cognitive functions after only one ECT session: a controlled study. Psychiatry Res 2008;158:389–394.
  17. Russell JC, Rasmussen KG, O’Connor MK, et al: Long-term maintenance ECT: a retrospective review of efficacy and cognitive outcome. J ECT 2009;19:4–9.

    External Resources

  18. Sienaert P, Vansteelandt K, Demyttenaere K, Peuskens J: Randomized comparison of ultra-brief and unilateral electroconvulsive therapy for major depression: cognitive side-effects. J Affect Disord 2010;122:60–67.
  19. Meeter M, Murre JMJ, Janssen SMJ, et al: Retrograde amnesia after electroconvulsive therapy: a temporary effect? J Affect Disord 2011;132:216–222.
  20. Warnell RL, Swartz CM, Thomson A: Clinically insubstantial cognitive side effects of bitemporal electroconvulsive therapy at 0.5 msec pulse width. Ann Clin Psychiatry 2011;23:257–262.
  21. MacQueen G, Parkin C, Marriott M, et al: The long-term impact of treatment with electroconvulsive therapy on discrete memory systems in patients with bipolar disorder. J Psychiatry Neurosci 2007;32:241–249.
  22. Roberts MA, Attah JR: Carbamazepine and ECT. Br J Psychiatry 1988;53:418.

    External Resources

  23. Sienaert P, Bouckaert F, Milo W, Peuskens J: Electroconvulsive therapy in Belgium. A questionnaire study on the practice of electroconvulsive therapy in Flanders and the Brussels Capital Region. J ECT 2005:21:3–6.
  24. Virupaksha HS, Shashidhara B, Thirthalli J, et al: Comparison of electroconvulsive therapy (ECT) with or without anti-epileptic drugs in bipolar disordered. J Affect Disord 2010;127:66–70.
  25. Scott AIF: The ECT Handbook. (Third Report of the Royal College of Psychiatrists’ Special Committee on ECT). Council Report CR128. London, The Royal College of Psychiatrists, 2005.
  26. Sienaert P, Peuskens J: Anticonvulsants during electroconvulsive therapy: review and recommendations. J ECT 2007;23:120–123.
  27. Jahangard L, Haghighi M, Bigdelou G, et al: Comparing efficacy of ECT with and without concurrent sodium valproate therapy in manic patients. J ECT 2012;28:118–123.
  28. Penland HR, Ostroff RB: Combined use of lamotrigine and electroconvulsive therapy in bipolar depression: a case series. J ECT 2006;22:142–147.
  29. Sienaert P, Roelens Y, Demunter H, et al: Concurrent use of lamotrigine and electroconvulsive therapy. J ECT 2011;27:148–152.
  30. Zarate CA, Tohen M, Baraibar G: Combined valproate or carbamazepine and electroconvulsive therapy. Ann Clin Psychiatry 1997;9:19–25.
  31. (accessed November 14, 2011).
  32. American Psychiatric Association: Diagnostic and Statistical Manual of Mental Disorders, ed 4. Washington, American Psychiatric Association, 2000.
  33. Barekatain M, Jahangard L, Haghighi M, et al: Bifrontal versus bitemporal electroconvulsive therapy in severe manic patients. J ECT 2008;24:199–202.
  34. Zschocke S: Klinische Elekroenzephalographie. Heidelberg, Springer, 2002.
  35. Guy W (ed): ECDEU Assessment for Psychopharmacology, Revised Edition. Rockville, NIMH Publication, 1976.
  36. Folstein M, Folstein S, McHugh PR: Mini-mental state: a practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 1975;12:189–198.
  37. Cohen J: Statistical Power Analysis for the Behavioural Sciences, ed 2. Hillsdale, Erlbaum, 1988.
  38. Peterchev AV, Rosa MA, Deng Z-D, et al: Electroconvulsive therapy stimulus parameters. Rethinking dosage. J ECT 2010;26:159–174.
  39. von Helversen B, Wilke A, Johnson T, et al: Performance benefits of depression: sequential decision making in a healthy sample and a clinically depressed sample. J Abnorm Psychol 2011;120:962–968.

Pay-per-View Options
Direct payment This item at the regular price: USD 38.00
Payment from account With a Karger Pay-per-View account (down payment USD 150) you profit from a special rate for this and other single items.
This item at the discounted price: USD 26.50